Company Directory / research

PrivateFor profitresearchMontreal, Canada
DalCor is developing precision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits
Size
11-50 people: larger than 33% of companies with a size listed
Age
11 years old.
Reach
Website ranked #3,751,253 in the world for traffic, about 3k visits a month.
GeneticsHealth CareMedicalPharmaceutical
Funding, as listed
$234M currency not stated
What the source datasets report. We have not watched these rounds ourselves.
Everything the source datasets list about DalCor Pharmaceuticals, field by field. Contact details are held but never shown.
The company
Where
Size and reach
Funding, as listed
About this record
Growth, as the source summarises it
DalCor Pharmaceuticals may be growing as it has successfully secured significant funding, with an $80 million investment in its Series D financing round. This influx of capital indicates investor confidence and provides the resources necessary for further development and potential expansion of operations. The repeated mention of this financial milestone across multiple news sources underscores its importance as a growth indicator for the company.
Summaries written by the source dataset, not by us, and not checked.
research in Canada.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 136,547 companies in Canada and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.